A primer myelofibrosis a Philadelphia-negatív krónikus myeloid neoplasiák közé tartozó ritka kórkép, amelyre jellemző a cytopeniák és hepatosplenomegalia kialakulása. A betegség etiológiája ugyan jelenleg sem ismert, de az utóbbi 10 – és még inkább a legutóbbi három – évben a patogenezisét és prognózisát tekintve ismereteink jelentősen bővültek. 2015-ben Magyarországon is elérhetővé vált a JAK2-gátló ruxolitinib a betegség kezelésére, amely a splenomegalia mérséklésén és a betegséghez társuló tünetek javításán túl a túlélési eredményeket is javíthatja. A primer myelofibrosis ellátásában tehát egyfajta szemléletváltás bontakozott ki, amely miatt időszerű a betegséggel kapcsolatos ismeretek összefoglalása. Orv. Hetil., 2016, 157(39), 1547–1556.
Moulard, O., Mehta, J., Fryzek, J., et al.: Epidemiology of myelofibrosis, essential thrombocythemia and polycythemia vera in the European Union. Eur. J. Hematol., 2014, 92(4), 289–297.
Titmarsh, G. J., Duncombe, A. S., McMullin, M. F., et al.: How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am. J. Hematol., 2014, 89(6), 581–587.
Dombi, P., Illés, Á., Demeter, J., et al.: Development of the Philadelphia-negative chronic myeloproliferative neoplasia registry in Hungary. [Philadelphia-negatív krónikus myeloproliferativ neoplasia regiszter magyarországi létrehozása.] Orv. Hetil. 2016, 157(3), 98–103. [Hungarian]
Campbell, P. J., Green, A. R.: The myeloproliferative disorders. N. Engl. J. Med., 2006, 355(23), 2452–2466.
Visfeldt, J., Andersson, M.: Pathoanatomical aspects of malignant haematological disorders among Danish patients exposed to thorium dioxide. APMIS, 1995, 103(1), 29–36.
Anderson, R. E., Hoshino, T., Yamamoto, T.: Myelofibrosis with myeloid metaplasia in survivors of the atomic bomb in Hiroshima. Ann. Intern. Med., 1964, 60(1), 1–18.
Akada, H., Yan, D., Zou, H., et al.: Condotional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood, 2010, 115(17), 3589–3597.
Cervantes, F.: How I treat myelofibrosis. Blood, 2014, 124(17), 2635–2642.
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., et al.: Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med., 2013, 369(25), 2379–2390.
Tefferi, A.: CME information: Primary myelofibrosis: 2014 update on diagnosis, risk-stratification and management. Am. J. Hematol., 2014, 89(9), 915–925.
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., et al.: Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27(9), 1861–1869.
Boveri, E., Passamonti, F., Rumi, E., et al.: Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br. J. Haematol., 2008, 140(2), 162–168.
Medinger, M., Skoda, R., Gratwohl, A., et al.: Angiogenesis and vascular endothelial growth factor/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br. J. Haematol., 2009, 146(2), 150–157.
Xu, M., Bruno, E., Chao, J., et al.: Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood, 2005, 105(11), 4508–4515.
Ferrant, A., Rodhain, J., Cauwe, F., et al.: Assessment of bone marrow and splenic erythropoiesis in myelofibrosis. Scand. J. Haematol., 1982, 29(5), 373–380.
Emanuel, R. M., Dueck, A. C., Geyer, H. L., et al.: Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J. Clin. Oncol., 2012, 30(33), 4098–4103.
Krähling, T., Balassa, K., Meggyesi, N., et al.: Complex molecular genetic diagnostic algorithm in the diagnosis of myeloproliferative neoplasms. [Komplex molekuláris genetikai vizsgálati algoritmus myeloproliferativ neoplasiák diagnosztikájában.] Orv. Hetil., 2014, 155(52), 2074–2081. [Hungarian]
Vannucchi, A. M., Barbui, T., Cervantes, F., et al.: Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2015, 26(Suppl. 5), v85–v99.
Arber, D. A., Orazi, A., Hasserjian, R., et al.: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016, 127(20), 2391–2405.
Kvasnicka, H. M., Thiele, J.: Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am. J. Hematol., 2010, 85(1), 62–69.
Barbui, T., Thiele, J., Passamonti, F., et al.: Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J. Clin. Oncol., 2011, 29(23), 3179–3184.
Cervantes, F., Dupriez, B., Pereira, A., et al.: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 2009, 113(13), 2895–2901.
Passamonti, F., Cervantes, F., Vannucchi, A. M., et al.: A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 2010, 115(9), 1703–1708.
Gangat, N., Caramazza, D., Vaidya, R., et al.: DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count and transfusion status. J. Clin. Oncol., 2011, 29(4), 392–397.
Andrikovics, H., Krahling, T., Balassa, K., et al.: Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica, 2014, 99(7), 1184–1190.
Tefferi, A., Lasho, T. L., Tischer, A., et al.: The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood, 2014, 124(15), 2465–2466.
Tefferi, A., Guglielmelli, P., Lasho, T. L., et al.:CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia, 2014, 28(7), 1494–1500.
Vannucchi, A. M., Guglielmelli, P., Rotunno, G., et al.: Mutation-enhanced International Prognostic Scoring System (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT Project. Blood, 2014, 124, 405.
Tefferi, A.: Management of primary myelofibrosis. 2015. http://www.uptodate.com
Masszi, T.: Novel approaches in the diagnosis and treatment of chronical myeloproliferative illnesses. [Újdonságok a krónikus myeloproliferatív betegségek diagnózisában és kezelésében.] Magy. Belorv. Arch., 2014, 67(5), 354–357. [Hungarian]
Martínez-Trillos, A., Gaya, A., Maffioli, M., et al.: Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann. Hematol., 2010, 89(12), 1233–1237.
Mesa, R. A., Steensma, D. P., Pardanani, A., et al.: A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood, 2003, 101(7), 2534–2541.
Quintás-Cardama, A., Kantarjian, H. M., Manshouri, T., et al.: Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J. Clin. Oncol., 2009, 27(28), 4760–4766.
Kröger, N., Giorgino, T., Scott, B. L., et al.: Impact of allogenic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood, 2015, 125(21), 3347–3350.
Kröger, N. M., Deeg, J. H., Olavarria, E., et al.: Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia, 2015, 29(11), 2126–2133.
Jaekel, N., Behre, G., Behning, A., et al.: Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant., 2014, 49(2), 179–184.
Verstovsek, S., Mesa, R. A., Gotlib, J., et al.: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med., 2012, 366(9), 799–807.
Harrison, C., Kiladjian, J. J., Al-Ali, H. K., et al.: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med., 2012, 366(9), 787–798.
Mead, A. J., Milojkovic, D., Knapper, S., et al.: Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br. J. Haematol., 2015, 170(1), 29–39.
Tefferi, A., Cervantes, F., Mesa, R., et al.: Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood, 2013, 122(8), 1395–1398.
Tallarico, M., Odenike, O.: Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies. Curr. Hematol. Malig. Rep., 2015, 10(2), 112–117.
Lavi, N., Horowitz, N., Brenner, B.: An update on the management of hematologic malignancies in pregnancy. Women’s Health, 2014, 10(3), 255–266.